NCT Number: NCT00285909
Moderate Alcohol Consumption, Risk of Cardiovascular Disease and Type 2 Diabetes: Influence of Alcohol Oxidation
Moderate alcohol consumption is associated with a decreased risk of cardiovascular disease and type 2 diabetes. The association of alcohol consumption with cardiovascular disease is mediated by a functional polymorphism of alcohol dehydrogenase 1c, but the effect of this polymorphism on alcohol metabolism is only investigated in vitro.
The risk reduction of moderate alcohol consumption for cardiovascular disease is explained largely by an increase of HDL cholesterol, but an increase of adiponectin concentrations after moderate alcohol consumption may also be involved. It seems likely that adiponectin is a mediator for the association of moderate alcohol consumption with type 2 diabetes. The mechanism by which moderate alcohol consumption increases adiponectin concentrations is unknown, but ppar-gamma activation may be involved.
effects of this polymorphism on mediators of this relation are not known. This study therefore investigates the effect of moderate alcohol consumption and the influence of alcohol dehydrogenase 1c polymorphism on ppar-gamma activated gene expression and risk factors of cardiovascular disease and type 2 diabetes.
Looking for future studies?
Notify MeKey information
Conditions
Age range
40 year–65 year
Sex eligibility
Female
Study type
Interventional
Phase
Not applicable
About this study
Objectives :
To investigate the effect of moderate alcohol consumption and influence of genetic variation of ethanol oxidation on:
- PPAR-γ activated gene expression
- Markers of coronary heart disease or type 2 diabetes
- Postprandial changes of HPA-axis activity among 36 postmenopausal women with ADH1C genotype associated with slow or fast alcohol metabolism.
Design : Randomized, controlled, not blinded crossover trial with 1 week wash-out preceding each treatment period
Participants
- Description : Apparently healthy postmenopausal women
- Number : 36
Study substances
- Test substance : White wine (ca. 25 g alcohol/day)
- Reference substance : White grape juice
Study treatments Treatment A: 250 ml white wine daily (ca. 25 g alcohol/day) Treatment B: 250 ml white grape juice daily
Study period
- Duration : two periods of 6 weeks preceded by 1 week wash-out period
Test parameters:
- Adiponectin mRNA expression
- Expression of PPAR-gamma activated genes: CD36, lipoprotein lipase, AP2
- Markers of cardiovascular disease (blood lipid profile, Lp-PLA2 activity, hs-CRP, fibrinogen)
- Markers of type 2 diabetes (adiponectin, adiponectin oligomers, insulin sensitivity)
- Parameters of alcohol oxidation (postprandial: blood alcohol and acetate, acetaldehyde)
- HPA-axis activity (postprandial & fasting: cortisol, ACTH, testosterone)
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy women aged 40 to 65 years
- Absence of menstrual period for at least 2 years
- Homozygotes for the ADH1C*1 or ADH1C*2 allele of ADH1C I349V polymorphism
- Alcohol consumption ≥ 5 and ≤ 21 units/week
Exclusion criteria
- Smoking
- Family history of alcoholism
- History of medical or surgical events that may significantly affect the study outcome, particularly metabolic or endocrine disorders and gastrointestinal disorders
- Recent blood donation
Treatment and study plan
Primary outcomes
-
PPAR-gamma activated gene expression
Secondary outcomes
-
Risk factors of cardiovascular disease and type 2 diabetes
-
Postprandial changes of HPA-axis activity
Sponsors and collaborators
Lead sponsor
TNO
Other
Registry information
Official study title
Effect of Moderate Alcohol Consumption on PPAR-γ Activity and Risk Markers of Metabolic Disease: Influence of Genetic Variation in Alcohol Oxidation
Important dates
- Study start
- 2006
- Study completion
- 2006
- First posted
- Feb 2, 2006
- Registry last updated
- Aug 16, 2006
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes
NCT01951339
Behavior, Cardiovascular Disease
Aurora, Colorado, United States
View Trial DetailsComplement and Cardiovascular Risk in Adolescents
NCT02821104
Cardiovascular Disease, Cardiovascular Diseases
Columbus, Ohio, United States
View Trial DetailsDietary Protein and Insulin Sensitivity Study
NCT00508937
Cardiovascular Disease, Cardiovascular Diseases
Berkeley, California, United States
View Trial DetailsA Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
NCT02019264
Body Weight, Cardiovascular Disease
Alexander City, Alabama, United States
View Trial Details